

Data Sheet: CellGro[®] / CellGenix[™]
Recombinant Human Thrombopoietin (rh TPO)
Preclinical Grade - Order No.: 1417-010 / 1417-050

Source	A DNA sequence encoding a truncated TPO protein was expressed in <i>E. coli</i>
Production	Terminal manufacturing steps and QC are performed in a GMP facility
Molecular mass	The methionyl form of the <i>E. coli</i> expressed truncated human TPO contains 181 amino acid residues (including an N-terminal His6-tag) and has a molecular mass of 20 kDa
Purity	≥ 95%, as determined by SDS-PAGE
Endotoxin level	< 1000 EU/mg, as determined by LAL gel clot test
Activity	≥ 5x10 ⁶ IU/mg IU/mg calibrated with the 1 st International Standard NIBSC, # 03/124 Measured in a cell proliferation assay using a human factor-dependent cell line, MO7e
Sterility	Sterility test of the vial product (direct inoculation)
Formulation	Lyophilized from a protein solution without carrier protein
Amount per vial	50 µg or 10 µg, as determined by BCA assay
Transport	Ambient temperature
Storage at	-20°C or below. Avoid repeated freeze-thaw cycles
Shelf life	Minimum 6 months from date of shipment
Intended use	For preclinical ex vivo use. Not intended for therapeutic use.

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel.: +49 761 88889-0 | Fax: +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro[®] is a registered trade mark of CellGenix GmbH in several European countries and Japan.
In the U.S.A. products are distributed under the name of CellGenix[™].